A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Ewing's sarcoma; Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Expanded access
- Sponsors Janssen Research & Development
- 12 Sep 2017 Results of a retrospective analysis assessing the efficacy and safety of trabectedin in an elderly patient subgroup with advanced leiomyosarcoma (LMS) or liposarcoma, presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results (n=1803) of retrospective analysis assessing efficacy and safety of patients treated long-term with trabectedin on the expanded access program, were presented at the 42nd European Society for Medical Oncology Congress.
- 17 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.